Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=32 Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Phase 2 N=21 MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma
Colorectal Neoplasms
Primary: pERK and pAKT Levels in Tumor Biopsies on C1D1 and C1D22 Post-administration of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Participants With Advanced…
Phase 2 N=36 Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Phase 2 N=47 RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma
Colorectal Cancer
Primary: Progression Free Survival at Six Months — 87 percentage of participants
Phase 2 N=28 Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Colorectal Cancer
Primary: Tumor Response Rate Based on Complete Response (CR)+ Partial Response (PR) + Stable Disease (SD) — 0; 1; 0; 4 Participants
Phase 2 N=51 BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Overall Rate of Response — 15 percentage of participants
Phase 2 N=42 Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
Phase 2 N=70 Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Colorectal Neoplasms
Primary: Overall Survival (OS) Time — 6.71 Months
Phase 3 N=3,397 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
Adenocarcinoma of the Colon · Stage III Colon Cancer
Primary: Disease-free Survival (Arms A and D: Wild-type KRAS Patients) — 74.6; 71.5 percentage of participants
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 2 N=36 Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
Colorectal Adenocarcinoma · RAS Wild Type · Stage IV Colorectal Cancer AJCC v7
Primary: Progression-Free Survival (PFS) — 9.7; 5.5 months — p=0.7609
Phase 2 N=94 A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response — 3; 20 Percentage of Participants — p=0.0735
Phase 2 N=56 Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon
Primary: Proportion of Patients Alive and Progression-free at 15 Months — .482 proportion of participants
Phase 2 N=124 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Colorectal Carcinoma
Primary: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor — 32.8; 34.9 Percentage of participants
Phase 2 N=64 Neoadjuvant Therapy for Locally Advanced Colon Cancer
Colon Cancer · Neoadjuvant Therapy
Primary: Tumor Regression Rate of MSS/pMMR Patients — 7 Participants
Phase 2 N=30 Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
Colorectal Cancer
Primary: Response Rate (Percentage of Participants With Partial or Complete Response) — 43 percentage of participants with response
Phase 2 N=215 Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
Colorectal Cancer
Primary: Progression Free Survival — 5.8; 7.2; 7.8 Months
Phase 2 N=63 Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
Colorectal Cancer
Primary: Median Time for Progression Free Survival — 15.8 Months
Phase 2 N=33 Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
Phase 2 N=29 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
Metastatic Colorectal Cancer
Primary: Response Rate of Lapatinib/Capecitabine. — 4; 1 participants
Phase 2 N=53 Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Colon Cancer · Colorectal Cancer · Rectal Cancer
Primary: Part 1: Number of Participants With Dose-limiting Toxicities — 0 participants
Phase 3 N=811 Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
Colorectal Cancer
Primary: OS in Participants With Left-sided Tumors — 37.85; 34.30 Months
Phase 2 N=16 Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Recurrent Colon Cancer
Primary: Progression Free Survival (PFS) — 255.921 days to progression
Phase 2 N=338 Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Neoplasm Metastasis · Colorectal Cancer
Primary: Best Overall Response Rate - Independent Review Committee (IRC) — 45.6; 35.7 percentage of participants — p=0.064
Phase 2 N=53 Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
Colorectal Cancer · Metastatic Cancer
Primary: Objective Response — 1; 3; 2 Participants
Phase 2 N=164 Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
Colorectal Carcinoma
Primary: Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization — 46.4; 47.4 percentage of participants
Phase 2 N=45 Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
Adenomatous Polyp · Recurrent Colon Cancer · Recurrent Rectal Cancer
Primary: Change in ACF pERK Levels
Phase 2 N=171 A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Colorectal Neoplasms
Primary: Progression Free Survival (PFS) — 5.72; 6.87; 7.59; 6.44 Months — p=0.8268
Phase 2 N=20 A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver
Metastatic Colorectal Cancer
Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…